The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-κB pathway

Carcinogenesis

Volumn 28, Issue 2, 2007, Pages 404-413

  Dell'Eva, Raffaella ^a   Minghelli, Simona ^a,b   Noonan, Douglas M ^c   Albini, Adriana ^a   Ferrari, Nicoletta ^a  

^a National Institute for Cancer Research   (Italy)

^b CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

^c UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEGUELIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METALLOPROTEINASE; PLACEBO; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN P21; PROTEIN P53; SURVIVIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; C57BL MOUSE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL INVASION; CELL MIGRATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; KAPOSI SARCOMA; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TUMOR GROWTH; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; BASE SEQUENCE; CELLS, CULTURED; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HOMEOSTASIS; HUMANS; NF-KAPPA B; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS P21(RAS); ROTENONE; SARCOMA, KAPOSI; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 33847259309     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl162     Document Type: Article

References (60)

1. Kelloff,G.J., Crowell,J.A., Steele,V.E. et al. (2000) Progress in cancer chemoprevention: Development of diet-derived chemopreventive agents. J. Nutr., 130, 467S-471S.
2. Pezzuto,J.M. (1997) Plant-derived anticancer agents. Biochem. Pharmacol., 53, 121-133.
3. Gerhauser,C., Mar,W., Lee,S.K., Suh,N., Luo,Y., Kosmeder,J., Luyengi,L., Fong,H.H., Kinghorn,A.D., Moriarty,R.M. et al. (1995) Rotenoids mediate potent cancer chemopreventive activity through transcriptional regulation of ornithine decarboxylase. Nat. Med., 1, 260-266.
4. Lee,H.Y., Oh,S.H., Woo,J.K. et al. (2005) Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J. Natl. Cancer Inst., 97, 1695-1699.
5. Udeani,G.O., Gerhauser,C., Thomas,C.F., Moon,R.C., Kosmeder,J.W., Kinghorn,A.D., Moriarty,R.M. and Pezzuto,J.M. (1997) Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid. Cancer Res., 57, 3424-3428.
6. Murillo,G., Kosmeder,J.W.II, Pezzuto,J.M. and Mehta,R.G. (2003) Deguelin suppresses the formation of carcinogen-induced aberrant crypt foci in the colon of CF-1 mice. Int. J. Cancer, 104, 7-11.
7. Gerhauser,C., Lee,S.K., Kosmeder,J.W., Moriarty,R.M., Hamel,E., Mehta,R.G., Moon,R.C. and Pezzuto,J.M. (1997) Regulation of ornithine decarboxylase induction by deguelin, a natural product cancer chemopreventive agent. Cancer Res., 57, 3429-3435.
8. Murillo,G., Salti,G.I., Kosmeder,J.W.II, Pezzuto,J.M. and Mehta,R.G. (2002) Deguelin inhibits the growth of colon cancer cells through the induction of apoptosis and cell cycle arrest. Eur. J. Cancer, 38, 2446-2454.
9. Hail,N.Jr and Lotan,R. (2004) Apoptosis induction by the natural product cancer chemopreventive agent deguelin is mediated through the inhibition of mitochondrial bioenergetics. Apoptosis, 9, 437-447.
10. Lee,H.Y., Suh,Y.A., Kosmeder,J.W., Pezzuto,J.M., Hong,W.K. and Kurie,J.M. (2004) Deguelin-induced inhibition of cyclooxygenase-2 expression in human bronchial epithelial cells. Clin. Cancer Res., 10, 1074-1079.
11. Chun,K.H., Kosmeder,J.W.II, Sun,S., Pezzuto,J.M., Lotan,R., Hong,W.K. and Lee,H.Y. (2003) Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J. Natl Cancer Inst., 95, 291-302.
12. Tosetti,F., Ferrari,N., De Flora,S. and Albini,A. (2002) 'Angioprevention': Angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J., 16, 2-14.
13. Jones,M.K., Wang,H., Peskar,B.M., Levin,E., Itani,R.M., Sarfeh,I.J. and Tarnawski,A.S. (1999) Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med., 5, 1418-1423.
14. Cai,T., Fassina,G., Morini,M., Aluigi,M., Masiello,L., Fontanini,G., D'Agostini,F. DeFlora,S., Noonan,D. and Albini,A. (1999) N-acetylcysteine inhibits endothelial cell invasion and angiogenesis. Lab. Invest., 79, 1151-1159.
15. Garbisa,S., Biggin,S., Cavallarin,N., Sartor,L., Benelli,R. and Albini,A. (1999) Tumor invasion: Molecular shears blunted by green tea. Nat. Med., 5, 1216.
16. Pages,G., Milanini,J., Richard,D.E., Berra,E., Gothie,E., Vinals,F. and Pouyssegur,J. (2000) Signaling angiogenesis via p42/p44 MAP kinase cascade. Ann. NY Acad. Sci., 902, 187-200.
17. Shiojima,I. and Walsh,K. (2002) Role of Akt signaling in vascular homeostasis and angiogenesis. Circ. Res., 90, 1243-1250.
18. Ackah,E., Yu,J., Zoellner,S. et al. (2005) Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. J. Clin. Invest., 115, 2119-2127.
19. Chen,J., Somanath,P.R., Razorenova,O., Chen,W.S., Hay,N., Bornstein,P. and Byzova,T.V. (2005) Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat. Med., 11, 1188-1196.
20. Albini,A., Dell'eva,R., Vene,R., Ferrari,N., Buhler,D.R., Noonan,D.M. and Fassina,G. (2005) Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-κB and Akt as targets. FASEB J., 20, 527-529.
21. Albini,A., Paglieri,I., Orengo,G. et al. (1997) The beta-core fragment of human Chorionic Gonadotrophin (hCG) inhibits growth of Kaposi's sarcoma-derived cells and a new immortalized Kaposi's sarcoma cell line. AIDS, 11, 713-721.
22. Albini,A., Iwamoto,Y., Kleinman,H.K., Martin,G.R., Aaronson,S.A., Kozlowski,J.M. and McEwan,R.N. (1987) A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res., 47, 3239-3245.
23. Albini,A., D'Agostini,F., Giunciuglio,D., Paglieri,J., Balansky,R.M. and De Flora,S. (1995) Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells by N-acetylcysteine. Int. J. Cancer, 61, 121-129.
24. Albini,A., Fontanini,G., Masiello,L., Tacchetti,C., Bigini,D., Luzzi,P., Noonan,D.M. and Stetler-Stevenson,W.G. (1994) Angiogenic potential in vivo by Kaposi sarcoma cell-free supernatants and HIV1-tat product: inhibition of KS-like lesions by TIMP-2. AIDS, 8, 1237-1244.
25. Muller,P.Y., Janovjak,H., Miserez,A.R. and Dobbie,Z. (2002) Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques, 32, 1372-1374, 1376, 1378-1379.
26. 1 cyclin-dependent kinases. Cell, 75, 805-816.
27. Kumar,R. and Hung,M.C. (2005) Signaling intricacies take center stage in cancer cells. Cancer Res., 65, 2511-2515.
28. Papapetropoulos,A., Fulton,D., Mahboubi,K., Kalb,R.G., O'Connor,D.S., Li,F., Altieri,D.C. and Sessa,W.C. (2000) Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J. Biol. Chem., 275, 9102-9105.
29. Ozes,O.N., Mayo,L.D., Gustin,J.A., Pfeffer,S.R., Pfeffer,L.M. and Donner,D.B. (1999) NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature, 401, 82-85.
30. Jeong,S.J., Pise-Masison,C.A., Radonovich,M.F., Park,H.U. and Brady,J.N. (2005) Activated AKT regulates NF-kappaB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene, 24, 6719-6728.
31. Huang,S., Pettaway,C.A., Uehara,H., Bucana,C.D. and Fidler,I.J. (2001) Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene, 20, 4188-4197.
32. Li,A., Dubey,S., Varney,M.L., Dave,B.J. and Singh,R.K. (2003) IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J. Immunol., 170, 3369-3376.
33. Toker,A. and Cantley,L.C. (1997) Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature, 387, 673-676.
34. Jiang,B.H., Zheng,J.Z., Aoki,M. and Vogt,P.K. (2000) Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc. Natl Acad. Sci. USA, 97, 1749-1753.
35. Romashkova,J.A. and Makarov,S.S. (1999) NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature, 401, 86-90.
36. Singh,R.P., Dhanalakshmi,S., Agarwal,C. and Agarwal,R. (2005) Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene, 24, 1188-1202.
37. Vivanco,I. and Sawyers,C.L. (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer, 2, 489-501.
38. Zhou,B.P., Liao,Y., Xia,W., Spohn,B., Lee,M.H. and Hung,M.C. (2001) Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol., 3, 245-252.
39. Mayo,L.D. and Donner,D.B. (2001) A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl Acad. Sci. USA, 98, 11598-11603.
40. Su,J.D., Mayo,L.D., Donner,D.B. and Durden,D.L. (2003) PTEN and phosphatidylinositol 3′-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: Evidence for an effect on the tumor and endothelial compartment. Cancer Res., 63, 3585-3592.
41. Zhou,B.P., Liao,Y., Xia,W., Zou,Y., Spohn,B. and Hung,M.C. (2001) HER-2/ neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol, 3, 973-982.
42. 1 arrest and apoptosis. Cancer Res., 54, 1169-1174.
43. el-Deiry,W.S., Tokino,T., Velculescu,V.E., Levy,D.B., Parsons,R., Trent,J.M., Lin,D., Mercer,W.E., Kinzler,K.W. and Vogelstein,B. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
44. Szak,S.T., Mays,D. and Pietenpol,J.A. (2001) Kinetics of p53 binding to promoter sites in vivo. Mol. Cell. Biol., 21, 3375-3386.
45. Reed,J.C. (2001) The Survivin saga goes in vivo. J. Clin. Invest., 108, 965-969.
46. Tran,J., Master,Z., Yu,J.L., Rak,J., Dumont,D.J. and Kerbel,R.S. (2002) A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl Acad. Sci. USA, 99, 4349-4354.
47. O'Connor,D.S., Schechner,J.S., Adida,C., Mesri,M., Rothermel,A.L., Li,F., Nath,A.K., Pober,J.S. and Altieri,D.C. (2000) Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am. J. Pathol., 156, 393-398.
48. Xiang,R., Mizutani,N., Luo,Y., Chiodoni,C., Zhou,H., Mizutani,M., Ba,Y., Becker,J.C. and Reisfeld,R.A. (2005) A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res., 65, 553-561.
49. Mirza,A., McGuirk,M., Hockenberry,T.N. et al. (2002) Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene, 21, 2613-2622.
50. Pfeffer,U., Ferrari,N., Dell'eva,R., Indraccolo,S., Morini,M., Noonan,D.M. and Albini,A. (2005) Molecular mechanisms of action of angiopreventive anti-oxidants on endothelial cells: Microarray gene expression analyses. Mutat. Res., 591, 198-211.
51. Aluigi,M.G., De Flora,S., D'Agostini,F., Albini,A. and Fassina,G. (2000) Antiapoptotic and antigenotoxic effects of N-acetylcysteine in human cells of endothelial origin. Anticancer Res, 20, 3183-3187.
52. Fassina,G., Vene,R., Morini,M., Minghelli,S., Benelli,R., Noonan,D.M. and Albini,A. (2004) Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate. Clin. Cancer Res., 10, 4865-4873.
53. Troussard,A.A., McDonald,P.C., Wederell,E.D. et al. (2006) Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res., 66, 393-403.
54. Huang,S., DeGuzman,A., Bucana,C.D. and Fidler,I.J. (2000) Nuclear factor-kappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin. Cancer Res., 6, 2573-2581.
55. Aggarwal,B.B. (2004) Nuclear factor-kappaB: The enemy within. Cancer Cell, 6, 203-208.
56. Albini,A., Tosetti,F., Benelli,R. and Noonan,D.M. (2005) Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res., 65, 10637-10641.
57. Albini,A. and Noonan,D.M. (2005) Rescuing COX-2 inhibitors from the waste bin. J. Natl. Cancer Inst., 97, 859-860.
58. Yoshida,S., Ono,M., Shono,T., Izumi,H., Ishibashi,T., Suzuki,H. and Kuwano,M. (1997) Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol. Cell. Biol., 17, 4015-4023.
59. Koch,A.E., Polverini,P.J., Kunkel,S.L., Harlow,L.A., DiPietro,L.A., Elner,V.M., Elner,S.G. and Strieter,R.M. (1992) Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science, 258, 1798-1801.
60. Luca,M., Huang,S., Gershenwald,J.E., Singh,R.K., Reich,R. and Bar-Eli,M. (1997) Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am. J. Pathol., 151, 1105-1113.